Clinical use of copeptin in migraine patients admitted to the emergency department



      The purpose of this study was to investigate the clinical use of copeptin to evaluate migraine attacks in the Emergency Department. An additional aim was to detect changes in serum copeptin levels in migraine patients during attack and attack-free periods.


      This prospective case–control study included 52 migraine patients and 51 healthy individuals with similar demographic characteristics. Blood samples were collected from migraine patients both in attack and attack-free periods.


      The mean copeptin levels in the patients group in the attack and attack-free periods were 689.28 and 576.68 pg/ml, respectively, whereas they were 608.68 pg/ml in the control group. There was a significant difference in the mean copeptin level in the attack period and attack-free periods (p = 0.026). The sensitivity and specificity of copeptin in detecting headache episodes in migraine patients were 58.8% and 60.7%, respectively, at a cut-off value of 388.67 pg/ml.


      This is the first study to investigate the diagnostic efficacy of serum copeptin levels in migraine patients. Although the diagnostic efficacy of serum copeptin levels for migraines was unsatisfactory, it could be helpful at management of migraine patients in ED.


      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Headache Classification Committee of the International Headache Society (IHS)
        The international classification of headache disorders, 3rd edition.
        Cephalalgia. 2018; 38: 1-211
        • Dodick D.W.
        Lancet. 2018; 391: 1315-1330
        • Gokdemir M.T.
        • Nas C.
        • Gokdemir G.S.
        Pentraxin 3 level in acute migraine attack with aura: patient management in the emergency department.
        Am J Emerg Med. 2019; (In press)
        • Friedman B.W.
        Migraine in the emergency department.
        Neurol Clin. 2019; 37: 743-752
        • Gilbert J.W.
        • Johnson K.M.
        • Larkin G.L.
        • Moore C.L.
        Atraumatic headache in US emergency departments: recent trends in CT/MRI utilisation and factors associated with severe intracranial pathology.
        Emerg Med J. 2012; 29: 576-581
        • Hampton K.K.
        • Esack A.
        • Peatfield R.C.
        • Grant P.J.
        Elevation of plasma vasopressin in spontaneous migraine.
        Cephalalgia. 1991; 1: 249-250
        • Hasselblatt M.
        • Köhler J.
        • Volles E.
        • Ehrenreich H.
        Simultaneous monitoring of endothelin-1 and vasopressin plasma levels in migraine.
        NeuroReport. 1999; 10: 423-425
        • Silberstein S.D.
        Migraine pathophysiology and its clinical implications.
        Cephalalgia. 2004; 24: 2):2-7
        • Morgenthaler N.G.
        • Struck J.
        • Jochberger S.
        • Dünser M.W.
        Copeptin: clinical use of a new biomarker.
        Trends Endocrinol Metab. 2008; 19: 43-49
        • Dobsa L.
        • Edozien K.C.
        Copeptin and its potential role in diagnosis and prognosis of various diseases.
        Biochem Med (Zagreb). 2013; 23: 172-190
        • Struck J.
        • Morgenthaler N.G.
        • Bergmann A.
        Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients.
        Peptides. 2005; 26: 2500-2504
        • Balanescu S.
        • Kopp P.
        • Gaskill M.B.
        • Morgenthaler N.G.
        • Schindler C.
        • Rutishauser J.
        Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states.
        J Clin Endocrinol Metab. 2011; 96: 1046-1052
        • Katan M.
        • Müller B.
        • Christ-Crain M.
        Copeptin: a new and promising diagnostic and prognostic marker.
        Crit Care. 2008; 12: 117
        • Nickel C.H.
        • Bingisser R.
        • Morgenthaler N.G.
        The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department.
        BMC Med. 2012; 10: 7
        • Stovner L.J.
        • Zwart J.A.
        • Hagen K.
        • Terwindt G.M.
        • Pascual J.
        Epidemiology of headache in Europe.
        Eur J Neurol. 2006; 13: 333-345
        • Stovner L.J.
        • Hagen K.
        • Jensen R.
        • Katsarava Z.
        • Lipton R.
        • Scher A.
        • et al.
        The global burden of headache: a documentation of headache prevalence and disability worldwide.
        Cephalalgia. 2007; 27: 193-210

      Linked Article